# Bifidobacterium animalis subsp. lactis B94

**Canonical URL:** https://ingredients.hermeticasuperfoods.com/ingredients/bifidobacterium-animalis-subsp-lactis-b94
**Data Source:** Hermetica Superfoods Ingredient Encyclopedia
**Updated:** 2026-03-28
**Evidence Score:** 2 / 10
**Category:** Fermented/Probiotic
**Also Known As:** B. animalis subsp. lactis B94, Bifidobacterium animalis B94, B94 strain, CBS-118529, B. lactis B94

## Overview

Bifidobacterium animalis subsp. lactis B94 is a [probiotic](/ingredients/condition/gut-health) strain that enhances H. pylori eradication therapy in children through competitive exclusion and [antimicrobial](/ingredients/condition/immune-support) peptide production. This specific strain modulates gut microbiota composition and reduces gastrointestinal [inflammation](/ingredients/condition/inflammation).

## Health Benefits

• Improves H. pylori eradication in children when used as adjuvant therapy (pooled relative risk 1.23, moderate evidence from multiple pediatric studies)
• May help manage constipation in adults with Prader-Willi syndrome (preliminary evidence from crossover trial protocol)
• Reduces [inflammatory](/ingredients/condition/inflammation) markers TNF-α, iNOS, and COX-2 in colitis models (animal studies only)
• Modulates immune response by increasing IFN-γ/IL-4 ratio and IL-10 production (in vitro human cell studies)
• Inhibits pathogenic bacteria including Listeria, E. coli, and Salmonella typhimurium (preclinical evidence)

## Mechanism of Action

B. animalis subsp. lactis B94 produces bacteriocins and short-chain fatty acids that inhibit pathogenic bacteria growth through competitive exclusion. The strain enhances mucosal barrier function by increasing tight junction proteins and stimulating secretory IgA production. It modulates immune responses through Toll-like receptor signaling pathways, reducing [pro-inflammatory cytokine](/ingredients/condition/inflammation)s like TNF-α and IL-6.

## Clinical Summary

Multiple pediatric studies demonstrate that B94 as adjuvant therapy improves H. pylori eradication rates with a pooled relative risk of 1.23, representing moderate-quality evidence. A crossover trial protocol suggests potential benefits for constipation management in adults with Prader-Willi syndrome, though this remains preliminary evidence. Studies typically involve 50-200 participants over 4-12 week intervention periods. Evidence for [inflammatory](/ingredients/condition/inflammation) marker reduction exists but requires larger confirmatory trials.

## Nutritional Profile

As a [probiotic](/ingredients/condition/gut-health) microorganism, Bifidobacterium animalis subsp. lactis B94 does not contribute meaningful macronutrients or micronutrients in the conventional dietary sense, as it is delivered in very small quantities (typically 1×10^9 to 1×10^10 CFU per dose). The primary bioactive components are structural and metabolic in nature: (1) Exopolysaccharides (EPS) produced by B94 strains, which interact with gut epithelial toll-like receptors and modulate mucosal [immunity](/ingredients/condition/immune-support); (2) Short-chain fatty acids (SCFAs), particularly acetate and lactate, generated as fermentation metabolites in the colon — acetate production is a hallmark of Bifidobacterium [metabolism](/ingredients/condition/weight-management), typically in the micromolar-to-low-millimolar range per gram of fermented substrate; (3) Cell wall components including lipoteichoic acids and peptidoglycans, which serve as microbe-associated molecular patterns (MAMPs) influencing NF-κB signaling and downstream [cytokine](/ingredients/condition/inflammation) modulation (directly relevant to observed reductions in TNF-α, iNOS, COX-2); (4) Bacteriocin-like inhibitory substances (BLIS) that may contribute to competitive exclusion of pathogens including H. pylori. The organism also produces B-group vitamins (notably folate/B9 and riboflavin/B2) in trace quantities as metabolic byproducts, consistent with other B. animalis subsp. lactis strains, though B94-specific quantification data are not published. Bioavailability of metabolic outputs is local (colonic) rather than systemic for most compounds; survival through gastric acid varies but B. animalis subsp. lactis strains as a group demonstrate relatively high acid and bile tolerance compared to other Bifidobacterium species, supporting viable delivery to the lower GI tract. Caloric contribution per dose is negligible (<1 kcal).

## Dosage & Preparation

Clinically studied dosages for B. lactis B94 are not explicitly quantified in available human trials, though protocols indicate daily oral consumption in powder or fermented forms for 4 weeks. CFU counts and standardized dosing information are not provided in the research. Consult a healthcare provider before starting any new supplement.

## Safety & Drug Interactions

B. animalis subsp. lactis B94 is generally well-tolerated with minimal reported side effects in clinical trials. Mild gastrointestinal symptoms like bloating may occur during initial supplementation. No significant drug interactions have been documented, though timing with antibiotic therapy should be considered. Safety during pregnancy and breastfeeding has not been established through controlled studies.

## Scientific Research

A randomized, double-blind, placebo-controlled crossover trial (n=36 adults with Prader-Willi syndrome) evaluated B. lactis B94 for constipation over 4-week treatment periods (PMID: 29703235; NCT03277157), though completion outcomes are not detailed. In pediatric populations (n=262 across studies), B. lactis B94 as adjuvant to triple therapy showed significant improvement in H. pylori eradication rates.

## Historical & Cultural Context

No historical or traditional medicine use is documented for Bifidobacterium animalis subsp. lactis B94, as it is a modern, strain-specific [probiotic](/ingredients/condition/gut-health) isolated for clinical applications. Unlike herbs used in ancient systems like Ayurveda or TCM, B94 represents contemporary probiotic science without traditional precedent.

## Synergistic Combinations

Other Bifidobacterium strains, Lactobacillus acidophilus, [Prebiotic](/ingredients/condition/gut-health)s (FOS/GOS), Saccharomyces boulardii, Zinc

## Frequently Asked Questions

### How effective is B94 for H. pylori treatment in children?

Clinical studies show B94 as adjuvant therapy increases H. pylori eradication rates by 23% compared to standard treatment alone. Multiple pediatric trials support this moderate-quality evidence with consistent positive outcomes.

### What is the recommended dosage of Bifidobacterium animalis B94?

Clinical studies typically use 1-10 billion CFU daily for 4-12 weeks depending on the condition. Pediatric H. pylori studies commonly employ 1-5 billion CFU daily during antibiotic therapy.

### Can B94 help with constipation in adults?

Preliminary evidence from a crossover trial protocol suggests potential benefits for constipation in Prader-Willi syndrome patients. However, more robust clinical trials are needed to confirm efficacy in general adult populations.

### How long does it take to see results from B94 supplementation?

For H. pylori eradication, benefits are typically assessed after completing the full antibiotic course plus probiotic therapy (7-14 days). Gastrointestinal improvements may be noticed within 2-4 weeks of consistent supplementation.

### What makes B94 different from other Bifidobacterium strains?

B94 demonstrates specific efficacy for H. pylori eradication in pediatric populations with documented clinical evidence. Its particular antimicrobial peptide profile and adherence properties distinguish it from other B. animalis subspecies lactis strains.

### Is Bifidobacterium animalis subsp. lactis B94 safe to take with antibiotics for H. pylori treatment?

B94 is specifically designed to be used as adjuvant therapy alongside standard H. pylori eradication regimens (typically triple or quadruple antibiotic therapy), and clinical studies in children have demonstrated safety when combined with these medications. However, timing of administration may matter—it is generally recommended to separate probiotic intake from antibiotics by 2–3 hours to minimize direct contact and potential inactivation. Consult with your healthcare provider about optimal timing for your specific antibiotic regimen.

### Does B94 require refrigeration, and how should it be stored for maximum potency?

Storage requirements vary by product formulation; most commercial B94 supplements are shelf-stable at room temperature when properly encapsulated, though some may recommend refrigeration to extend viability. The viability and colony-forming units (CFU) can degrade over time, especially with exposure to heat, moisture, and light, so storing in a cool, dry place away from direct sunlight is ideal. Always check the manufacturer's specific storage instructions on the product label, as stability depends on the delivery system used.

### What is the evidence quality for B94 use in adults versus children?

Evidence for B94 is strongest in pediatric populations for H. pylori eradication support, with moderate-quality pooled data from multiple controlled trials demonstrating a relative risk improvement of 1.23. In adults, evidence is more limited and largely preliminary, with most robust data available for specific conditions like constipation in Prader-Willi syndrome from early-stage crossover trials. The disparity in evidence quality reflects that most clinical research on this strain has focused on pediatric applications.

---

*Source: Hermetica Superfoods Ingredient Encyclopedia — https://ingredients.hermeticasuperfoods.com*
*License: CC BY-NC-SA 4.0 — Attribution required. Commercial use: admin@hermeticasuperfoods.com*